[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Given the clinical picture \u2013 HIV infection with low CD4, neurological symptoms (headaches, blurred vision, confusion, ataxia, memory impairment), CSF findings (lymphocytic pleocytosis, EBV positivity), and MRI findings (solitary, ring-enhancing lesion in the corpus callosum) \u2013 the most likely diagnosis is **Progressive Multifocal Leukoencephalopathy (PML)**.\n\nWhile EBV is detected in CSF, it's often reactivated in PML due to the immunosuppression, not the primary cause of the lesion. The MRI findings are classic for PML.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "That's a good question to ask when discussing treatment options.\n\n**Enfuvirtide** is the antiretroviral medication that acts on the gp41 subunit of the HIV envelope glycoprotein. It's a fusion inhibitor. \n\nHowever, it's not typically a first-line agent due to its administration route (subcutaneous injection) and tolerability. Modern regimens usually start with integrase inhibitors, or other classes with fewer side effects and simpler dosing.",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "This patient is most likely in the **acute HIV infection** stage. \n\nHere's why:\n\n*   **Recent positive HIV test + symptoms:** Fever, malaise, and lymphadenopathy are common symptoms of acute HIV infection, occurring soon after initial infection.\n*   **Normal CD4 count:** A CD4 count of 650/mm3 is within the normal range, indicating the immune system hasn't been significantly impacted *yet*. CD4 counts typically decline in later stages.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "This patient likely has disseminated *Nocardia* infection, given the cavitary lung disease, acid-fast bacilli, and immunocompromised state. \n\nThe most appropriate drug is **trimethoprim-sulfamethoxazole (TMP-SMX)**.\n\nIts mechanism of action is sequential blockade of two steps in the folic acid synthesis pathway. Specifically, **sulfamethoxazole inhibits dihydropteroate synthase, while trimethoprim inhibits dihydrofolate reductase.** This ultimately prevents bacterial DNA synthesis.",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "That's a good question, and a logical approach to HIV treatment research. \n\nThe most likely target would be **the HIV envelope glycoprotein gp120**.\n\nHere's why:\n\n*   **Neutralization:** gp120 is crucial for initial viral entry into cells. Antibodies that bind gp120 can *neutralize* the virus by blocking its attachment to CD4 receptors.\n*   **Accessibility:** It's highly exposed on the viral surface, making it readily accessible to antibodies.\n*   **Natural Response:** The natural humoral response *does* target gp120, meaning an enhanced antibody to this region has a good starting point.\n\nWhile gp41 (the other envelope protein) is also a target, gp120 is generally considered the primary target for neutralizing antibodies.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "That clinical picture strongly suggests *Aspergillus* species. The fibrocavitary lesion, hemoptysis, and acute-angle branching septate hyphae on biopsy are classic findings in pulmonary aspergillosis, particularly in an immunocompromised host like a person with HIV. \n\nIt's important to quickly initiate appropriate antifungal therapy.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "Valganciclovir, combined with zidovudine, carries a significant risk of **myelosuppression** \u2013 specifically, neutropenia and anemia. Both drugs can suppress bone marrow function, and the combination increases that risk substantially.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "That's a very common and important concern. The most appropriate test immediately after delivery would be **HIV-1 DNA PCR (polymerase chain reaction)**. \n\nHere's why:\n\n*   **Early Detection:** PCR detects the virus itself, not antibodies. Newborns have maternal antibodies that can cross the placenta and give a false positive on antibody tests for up to 18 months.\n*   **Specificity:** PCR can identify viral presence very early in life, even before the baby develops its own antibodies.\n*   **Timing:** It should be done within 24-48 hours of birth, ideally.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "This is a complex ethical and legal situation. The most appropriate next step is to **strongly counsel the patient about the legal and ethical obligations regarding partner notification.** \n\nSpecifically, explain that while you respect his desire for confidentiality, many jurisdictions *require* reporting of HIV to public health authorities, who will then facilitate partner notification. You must also explain that knowingly transmitting HIV is a crime.\n\nSimultaneously, prepare to navigate the conflict of interest regarding his wife, who is also your patient. You will likely need to discuss this with legal counsel. Do *not* breach confidentiality by informing the wife directly at this stage.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the clinical presentation \u2013 acute epigastric pain radiating to the back, nausea, vomiting, elevated amylase and lipase, and CT findings of pancreatitis \u2013 the most likely etiology is **acute pancreatitis**. \n\nWhile her HIV infection is part of her medical history, it's less directly linked to *acute* pancreatitis than other factors. Alcohol use and, potentially, certain HIV medications (though we don't know which ones yet) can be contributing factors. Diabetes is also a risk factor.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "That's a good question, and a critical scenario.\n\nZidovudine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI). Therefore, the biological process most disrupted by its action is **reverse transcription** \u2013 the process by which HIV converts its RNA genome into DNA. \n\nEssentially, AZT acts as a faulty building block, halting the creation of viral DNA.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "That's a good question, reflecting a growing area of research. Here's a brief overview:\n\n**Latent HIV-1:** Studies show altered DNA methylation patterns in latently infected cells (specifically within the HIV provirus, and also in host genes). Generally, increased methylation at the proviral LTR (Long Terminal Repeat) is associated with transcriptional silencing \u2013 a key feature of latency. However, it's not a simple on/off switch; methylation patterns are complex and can vary.\n\n**Active Infection:** Active HIV-1 infection is also linked to changes in DNA methylation, both in the provirus and host cells. These changes can influence viral replication, immune activation, and disease progression. The direction of change (hyper- or hypomethylation) is variable and depends on the specific gene/region and stage of infection.\n\n**In essence:** DNA methylation is dynamically altered in both latency and active infection, influencing viral gene expression and host immune responses. It's a potential target for therapeutic interventions aiming to \"kick\" the virus out of latency or modulate the immune response.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]